Partnership deal will support development of potential new antimalarial

31 Mar 2011

Posted by: Paul Chinnock - Editorial Team

Comments (1)

A new treatment for malaria could be on the way with the announcement that the Medicines for Malaria Venture (MMV) and Anacor Pharmaceuticals have entered into a development agreement relating to an Anacor compound - AN3661.

MMV is a not-for-profit public-private partnership that aims to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Anacor is a US biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Under the agreement, Anacor and MMV will work together on the development of AN3661 through human proof-of-concept studies. AN3661 was developed as part of a research agreement signed last year; AN3661 is the first candidate arising out of this agreement to move into preclinical development.

Anacor is also active in the search for treatments for other infectious diseases of poverty and has established partnership arrangements with: the Global Alliance for TB Drug Development; with the Drugs for Neglected Diseases initiative (human African trypanosomiasis, visceral leishmaniasis and Chagas disease); the University of California San Francisco and the New York Blood Center (onchocerciasis); and with the Institute for OneWorld Health (diarrhoeal disease.)

More details are available in an Anacor press release.


  1. Leah Gibbs Says:

    Malaria with one million deaths and about 500 million new cases reported annually is a challenge to drug therapy and discovery. As current antimalarial therapeutics become increasingly ineffective because of parasitic resistance, there exists an urgent need to develop and pursue new therapeutic strategies. Antimalarial drug development can follow several strategies, ranging from minor modifications of existing agents to the design of novel agents that act against new targets. Recent advances in our knowledge of parasite biology as well as the availability of the genome sequence provide a wide range of novel targets for drug design. Several promising targets for drug intervention have been revealed in recent years. This review discusses novel molecular targets of the malaria parasite available to the drug discovery scientist.

Leave a Reply

TropIKA Blogs
Recent Commented Posts
Blog Archives
March 2011
« Feb   May »